Charles Perla, MD
Cardiovascular Disease · Liverpool, NYNPI 1730180589
Payments from drug & device makers
Across 75 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$179
- Johnson & Johnson$154
- Sanofi$125
- Boston Scientific$71
- Regeneron Healthcare Solutions, Inc.$71
- Lantheus Medical Imaging, Inc.$70
- plus $650 from 16 others
What the payments were for
- Speaking & faculty fees$1259%
- Food & beverage$1,19591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $179 |
| Johnson & Johnson | 12 | $154 |
| Sanofi | 1 | $125 |
| Boston Scientific | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 5 | $71 |
| Lantheus Medical Imaging, Inc. | 1 | $70 |
| Amarin Pharma, Inc. | 4 | $69 |
| Gilead | 5 | $68 |
| Boehringer Ingelheim | 5 | $66 |
| Biotronik Inc. | 1 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Novartis | 4 | $55 |
| Bayer | 3 | $51 |
| AstraZeneca | 4 | $48 |
| Pfizer | 4 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $27 |
| Medtronic | 2 | $24 |
| Vifor Pharma, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MULTAQ$125
How this compares
$1,320 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 320 | $313,611 |
| XareltoRivaroxaban | 86 | $93,740 |
| EntrestoSacubitril/Valsartan | 63 | $83,344 |
| Repatha SureclickEvolocumab | 53 | $51,939 |
| MultaqDronedarone Hcl | 22 | $33,299 |
| JardianceEmpagliflozin | 19 | $28,694 |
| FarxigaDapagliflozin Propanediol | 26 | $19,322 |
| VascepaIcosapent Ethyl | 19 | $14,850 |
| Repatha SyringeEvolocumab | 17 | $9,399 |
| Metoprolol Succinate | 681 | $9,328 |
| Icosapent Ethyl | 31 | $9,169 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $5,842 |
| Atorvastatin Calcium | 397 | $3,897 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 186 | $2,135 |
| Amlodipine Besylate | 404 | $2,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $313,611320 claims |
| Johnson & JohnsonXarelto | $154 | $93,74086 claims |
| NovartisEntresto | $55 | $83,34463 claims |
| Sanofi-aventis U.S. LLCMultaq | $56 | $33,29922 claims |
| Boehringer IngelheimJardiance | $66 | $28,69419 claims |
| AstraZenecaFarxiga | $48 | $19,32226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Liverpool
- Ayman IskanderLiverpool$1.3M
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.